This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Impax Laboratories Management Discusses Q2 2012 Results - Earnings Call Transcript

Impax Laboratories (IPXL)

Q2 2012 Earnings Call

July 31, 2012 11:00 am ET


Mark Donohue - Senior Director of Investor Relations & Corporate Communications

Larry Hsu - Chief Executive Officer, President and Director

Bryan M. Reasons - Acting Chief Financial Officer

Michael J. Nestor - Divisional President of Impax Pharmaceuticals

Carole S. Ben-Maimon - President of Global Pharmaceuticals Division


Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Corey B. Davis - Jefferies & Company, Inc., Research Division

Randall Stanicky - Canaccord Genuity, Research Division

Elliot Wilbur - Needham & Company, LLC, Research Division

Gregory Waterman - Goldman Sachs Group Inc., Research Division

Sumant S. Kulkarni - BofA Merrill Lynch, Research Division

David Amsellem - Piper Jaffray Companies, Research Division

Michael Kallai Tong - Wells Fargo Securities, LLC, Research Division

Dewey Steadman

Ken Cacciatore - Cowen and Company, LLC, Research Division

Ami Fadia - UBS Investment Bank, Research Division

James F. Molloy - ThinkEquity LLC, Research Division



Good morning. My name is Reshaira, and I will be your conference operator today. At this time, I would like to welcome everyone to the Impax Laboratories Second Quarter 2012 Earnings Conference Call. [Operator Instructions] Thank you, Mr. Donohue, you may begin your conference.

Mark Donohue

Thank you. Good morning, and welcome to Impax's second quarter 2012 earnings conference call. This morning, Dr. Larry Hsu, our President and Chief Executive Officer; and Bryan Reasons, our acting Chief Financial Officer, will have some comments on our second quarter results and other business items. Following their prepared remarks, both will be available to take any questions you may have.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs